MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Perlegen Sciences, Inc. announced today that it has formed a personalized medicine collaboration with an undisclosed electronic medical records (EMR) provider to identify and develop genetic markers to help predict how patients are likely to respond to specific medical treatments. Perlegen and its partner will mine data from the EMR’s growing information warehouse, which currently contains clinical treatment and outcome data on roughly four million patients, to enable the identification of subsets of patient records which meet highly specific inclusion and exclusion criteria. Working via each patient’s individual care provider, Perlegen will then seek to obtain DNA from these highly-selected patients in a HIPAA-compliant, IRB-approved manner, to help physicians address various medical situations in which genetically-based predictions about treatment response may help significantly improve patient care.
